Vancouver, Canada-based Wildflower Brands, Inc. sent a rep to the US Food and Drug Administration’s public hearing on cannabis May 31, with the message that CBD-containing cosmetics and dietary supplements can be adequately regulated without consigning such products to the drug category.
“While we recognize that CBD has demonstrable medical use when highly refined and used in a controlled clinical setting, we also think there is sufficient evidence to safely regulate plant extracts containing CBD in a dietary
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?